OncoCipherPATIENT
Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.

← All Supported Cancers

Ovarian, Fallopian Tube & Primary Peritoneal Cancer — Options & Clinical Trial Reference

Source-cited reference covering germline/somatic BRCA1/2, HRD status, Folate Receptor-alpha (FRa), platinum interval, maintenance categories, and recruiting trials.

Module v6.0.0-nofda-prototype · Curated SHA-256: 26ecbff635059c76 · Trial Snapshot: 2026-10-23

Key Biomarkers & Decision Factors:
biomarkerspending_status_valuesequivocal_valuesversionstatuscarried_from

Unranked Guideline & FDA-Label Option Categories (22 total)

Option / PathwayCategoryPrimary Sources
Mirvetuximab soravtansine
Selected FRα/test/prior-regimen conditions are source-linked.
selected_indicated_therapymirv, mirv-label
Pembrolizumab + paclitaxel ± bevacizumab
Selected PD-L1/test/prior-regimen conditions are source-linked.
selected_indicated_therapypembro, pembro-label, paclitaxel-label, bev-label
Relacorilant + nab-paclitaxel
Selected prior-regimen and prior-bevacizumab conditions are source-linked.
selected_indicated_therapyrela, rela-label, nab-paclitaxel-label
Paclitaxel (single agent)
Conventional recurrent-disease discussion candidate.
conventional_therapynci, paclitaxel-label
Pegylated liposomal doxorubicin (single agent)
Conventional recurrent-disease discussion candidate.
conventional_therapynci, pld-label
Topotecan (single agent)
Conventional recurrent-disease discussion candidate.
conventional_therapynci, topotecan-label
Gemcitabine (single agent; off-label here)
NCI discusses single-agent use in platinum-resistant recurrence.
conventional_therapynci, gemcitabine-label
Bevacizumab + paclitaxel
Named bevacizumab partner with a separate prior-chemotherapy count.
selected_indicated_therapybev-label, nci, paclitaxel-label
Bevacizumab + pegylated liposomal doxorubicin
Named bevacizumab partner with a separate prior-chemotherapy count.
selected_indicated_therapybev-label, nci, pld-label
Bevacizumab + topotecan
Named bevacizumab partner with a separate prior-chemotherapy count.
selected_indicated_therapybev-label, nci, topotecan-label
Pembrolizumab alone (MSI-H or dMMR solid tumours)
Gated only on what KEYTRUDA §1.8 states and the record holds: MSI-H or dMMR result, an FDA-authorized test, and progression after earlier treatment. Route: a subcutaneous form, KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa), is approved for the same MSI-H or dMMR solid-tumour use; it has its own dose and route and is not interchangeable with intravenous pembrolizumab.
selected_indicated_therapypembro-msi-label
Dostarlimab alone (dMMR solid tumours)
Current JEMPERLI §1.3/§2.1 plus the therapy-specific FDA companion-diagnostic intended use: reviewed VENTANA dMMR or MI Cancer Seek MSI-H. An unverified or different assay calls for report/intended-use review; it is not automatically a clinical exclusion or an instruction to repeat IHC.
selected_indicated_therapyjemperli-label-v15-selection, ventana-p210001-jemperli, mi-cancer-seek-p240010-jemperli, dostarlimab-label
Trastuzumab deruxtecan alone (HER2 IHC 3+ solid tumours)
Gated only on what ENHERTU §1.6 states and the record holds: HER2 IHC 3+ and earlier systemic treatment. The label names no scoring criteria for this use and says no FDA-authorized test for it is available, so neither is a gate.
selected_indicated_therapytdxd-label
Clinical-trial review
Trial consideration is part of review in this setting.
care_pathwaynci
Supportive and palliative care review
Concurrent symptom relief and goals-of-care review.
care_pathwaypalliative

View all 22 Ovarian, Fallopian Tube & Primary Peritoneal Cancer reference options →

Recruiting Clinical Trials (342 curated)

NCT IDStudy TitlePhase
NCT00539162Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk WomenNA
NCT01174121Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerPHASE2
NCT01558544Cryopreservation of Ovarian TissueNA
NCT02830724Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersPHASE1|PHASE2
NCT03011684Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors TrialPHASE3
NCT03067181Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell TumorsPHASE3
NCT03412877Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic CancerPHASE2
NCT03544983Genetic Education in BRCA FamiliesNA
NCT03564340Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersPHASE1|PHASE2
NCT03604315Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTFPHASE1
NCT03686124ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsPHASE1|PHASE2
NCT03854110A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With GemcitabinePHASE1

View all 342 Ovarian, Fallopian Tube & Primary Peritoneal Cancer clinical trials →